Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

745 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Feasibility and efficacy of chemoradiotherapy with concurrent split-dose cisplatin after induction chemotherapy with docetaxel/cisplatin/5-fluorouracil for locally advanced head and neck cancer.
Yokota T, Shibata M, Hamauchi S, Shirasu H, Onozawa Y, Ogawa H, Onoe T, Kawakami T, Furuta M, Inoue H, Fushiki K, Onitsuka T. Yokota T, et al. Among authors: furuta m. Mol Clin Oncol. 2020 Oct;13(4):35. doi: 10.3892/mco.2020.2105. Epub 2020 Jul 31. Mol Clin Oncol. 2020. PMID: 32802331 Free PMC article.
Multi-center clinical evaluation of streptozocin-based chemotherapy for advanced pancreatic neuroendocrine tumors in Japan: focus on weekly regimens and monotherapy.
Shibuya H, Hijioka S, Sakamoto Y, Ito T, Ueda K, Komoto I, Kobayashi N, Kudo A, Yasuda H, Miyake H, Arita J, Kiritani S, Ikeda M, Imaoka H, Ueno M, Kobayashi S, Furuta M, Nagashio Y, Murohisa G, Aoki T, Matsumoto S, Motoya M, Azemoto N, Itakura J, Horiguchi S, Yogi T, Kawagoe T, Miyaoka Y, Imamura F, Senju M, Arioka H, Hara K, Imamura M, Okusaka T. Shibuya H, et al. Among authors: furuta m. Cancer Chemother Pharmacol. 2018 Oct;82(4):661-668. doi: 10.1007/s00280-018-3656-y. Epub 2018 Jul 27. Cancer Chemother Pharmacol. 2018. PMID: 30054710
Evaluation of Irinotecan and Trifluridine/Tipiracil as Fourth-line Treatments After Third-line Nivolumab for Advanced Gastric Cancer.
Hayashi K, Furuta M, Furusawa K, Hamaguchi T, Watanabe M, Inokuchi Y, Onuma S, Hashimoto I, Suematsu H, Nagasawa S, Kanematsu K, Yamada T, Notsu A, Ogata T, Oshima T, Machida N, Furuse J, Maeda S. Hayashi K, et al. Among authors: furuta m. Anticancer Res. 2023 Jun;43(6):2831-2840. doi: 10.21873/anticanres.16452. Anticancer Res. 2023. PMID: 37247885
Prognostic Impact of Immune-related Adverse Events in Gastric Cancer Patients Treated With Nivolumab.
Suematsu H, Kano K, Yamada T, Hashimoto I, Watanabe H, Takahashi K, Watanabe M, Hayashi K, Kaneta Y, Furuta M, Inokuchi Y, Machida N, Aoyama T, Tamagawa H, Yukawa N, Rino Y, Masuda M, Ogata T, Oshima T. Suematsu H, et al. Among authors: furuta m. Anticancer Res. 2022 Mar;42(3):1535-1540. doi: 10.21873/anticanres.15626. Anticancer Res. 2022. PMID: 35220249
745 results